Navigation Links
Neurobiological Technologies, Inc. (Nasdaq: NTIID)
Date:9/19/2007

Q4/07 Review Issued by Scimitar Equity Research, Inc.

BOSTON, Sept. 19 /PRNewswire/ -- Scimitar Equity Research, Inc. (Scimitar) issues a review of Neurobiological Technologies, Inc. (Nasdaq: NTIID), entitled, "The Secret of Success is Constancy of Purpose: VIPRINEX(TM) Could Restore Stroke Patients to Fuller Lives and They Will Be the Real Miracle of NTII's Achievement".

This review is available at our website: http://www.scimitarequity.com.

Neurobiological Technologies, Inc. (NTII) is a biotechnology company engaged in the business of acquiring and developing central nervous system related drug candidates. NTIID is focused on therapies for neurological conditions that occur in connection with ischemic stroke, brain cancer, Alzheimer's disease and dementia. NTIID's strategy is to in-license and develop later-stage drug candidates that target major medical needs and that can be rapidly commercialized. NTIID's experienced management team oversees the human clinical trials necessary to establish preliminary evidence of efficacy. For further information, please visit NTII's website at http://www.ntii.com.

NTII's common stock will trade under the symbol "NTIID" for 20 trading days to denote the recent reverse (7 for 1) split. After that time, the symbol will revert back to "NTII". Holders of record will be receiving instructions from NTII's transfer agent to define the procedures of surrendering their pre-split share certificates as well as assign their receipt of the new post-split certificates. NTIID's primary objective in authorizing the reverse split is to raise the share trading price of its common stock and to increase the number of shares of authorized but un-issued common stock.

Scimitar Equity Research, Inc. provides sponsored equity research of the health sciences industry for the institutional and investment communities. We certify that all the views expressed in this review, accurately reflect our personal views about NTIID (Nasdaq) and its or their securities. No part of our compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views contained in this review and we will not have any investment banking relationships or personal investment in any sponsored company. Investors are advised that this analysis and review is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy. Scimitar was paid for preparing this review. This analysis and review does not have regard to the specific investment objectives, financial situation and the information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Any opinions expressed are statements of our own judgment as of the date of publication and are subject to change without notice. Please read all our important disclosures.

CONTACT:

Scimitar Equity Research, Inc.

Henry W. McCusker

Director of Research

phone: (617) 559.1080

fax: (617) 559.1083

e-mail: hwm@scimitarequity.com


'/>"/>
SOURCE Scimitar Equity Research, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... ... February 04, 2016 , ... Shimadzu ... quad LC-MS, host live demos and poster sessions, and present on the analysis ... conference takes place March 6 to 10 at the Georgia World Congress Center ...
(Date:2/4/2016)... , Feb. 4, 2016 Beike Biotechnology, the ... medical institutions attended a ceremony in late 2015 to ... cell therapy in 2016. --> ... Translation Platform for Personalized Cell Therapy" was hosted by ... Production Center, both subsidiaries of Beike Biotechnology Co., Ltd. ...
(Date:2/4/2016)... British Columbia and MENLO PARK, Calif. ... (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical company ... today announced that it will present at the 18 ... Monday, February 8, 2016 at 10:00 a.m. EST in ... Bacha , DelMar,s president and CEO, will provide an update ...
(Date:2/4/2016)... Feb. 4, 2016 ContraVir Pharmaceuticals, Inc. (NASDAQ: ... development and commercialization of targeted antiviral therapies, announced today ... Conference 2016, to be held February 8-9, 2016, at ... 2016 Disruptive Growth & Healthcare Conference, taking place in ... 2016. James Sapirstein , Chief Executive Officer ...
Breaking Biology Technology:
(Date:1/7/2016)... NEW YORK , Jan. 7, 2016 ... as regional markets for biometric technologies and devices, identifying ... application market for various types of biometric devices. Includes ... report to: Identify newer markets and explore the ... of biometric devices. Examine each type of biometric technology, ...
(Date:1/7/2016)... MIAMI , Jan. 7, 2016  A United ... became the first court in the country to interpret ... landmark lawsuit to go forward against the photo website ... LLP. BRIAN NORBERG vs. SHUTTERFLY, INC.; ... the plaintiff alleges that Shutterfly violates the Illinois Biometric ...
(Date:1/6/2016)... , Jan. 6, 2016 Based on ... Frost & Sullivan recognizes MorphoTrak, LLC, a U.S. ... American Frost & Sullivan Company of the Year ... scanning technology, Morpho Wave™ , has consolidated the ... fingerprint biometrics market. Morpho Wave is a ...
Breaking Biology News(10 mins):